Optimize Lead Choice

Make decisions preclinically when comparing & combining cell therapies with new modalities1

Apply the power of polyfunctional strength to identify functional immune cell subsets which correlate with in vivo activity.

Download application highlight

Research Area

Development Stage

Optimize

Goal

Identify differences and mechanism in combined cell therapies

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

PSI revealed differences in control and new combination therapy, enhancing decision making

polyfunctional cell

Finding

NKTR-214 elicited more polyfunctional subsets than IL-2, which correlates with results from complementary technologies

follow our data

Follow Our Data

See the latest published data in Checkpoint & Combination Immunotherapies

Polyfunctionality and Polyfunctional Strength are considerably increased in samples treated with ACT+NKTR-214 vs ACT+IL-2. Sorted antigen-specific CD8+ T cells Thy1.+ from tumors and spleen D7 after ACT+NKTR-214 or ACT+IL-2 (3 mice/group) were stimulated and stained with anti-mouse CD8.

NKTR2-14 elicited more polyfunctional cell subsets in the adoptively transferred TCR-T cells in spleen and tumor compared to IL-2.

Download application highlight
Polyfunctional Strength

Solution

IsoPlexis finds critical differences

Immuno-PET imaging using cys-diabody (cDb) targeting CD8 in vivo shows significant T cells expansion in spleen for ACT+NKTR-214-treated mice. Representative CD8 cys-diabody immuno-PET/CT images acquired on D5 after treatment with ACT+IL-2 or ACT+NKTR-214 (n=3/group). I.V. injection of Zr-89 labeled anti-CD8 cDb was performed 24h prior imaging of C57/BL6 mice.

NKTR-214 increases expression of genes associated with T cell cytotoxicity and memory. Clustering of chemokines and their receptors, showing a general trend of increased expression in the ACT+NKTR-214 group.1

Request a Seminar

Request a Seminar
Discover IsoLight